Hepatocellular Carcinoma

Malignant Liver Tumors: Current and Emerging Therapies: Third Edition

Volumn , Issue , 2009, Pages 317-323

  Takayama, Tadatoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

"Degree of liver damage"; Discrepancies between the Western and the Eastern guidelines; Hepatocellular carcinoma; The Barcelona clinic liver cancer (BCLC); The cancer of the liver Italian program (CLIP); Transarterial chemoembolization (TACE); Western guidelines

Indexed keywords

EID: 79953755166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317053.ch26     Document Type: Chapter

References (34)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis 1999; 19: 332-8.
3. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL conference. J Hepatol 2001; 35: 421-30.
4. Poon RT, Fan ST, Tsang FH, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 466-86.
5. Ryder SD. Guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl III):iii1-8.
6. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006; 12: 828-9.
7. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
8. Helton WS, Strasberg SM. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. HPB Surg 2003; 5: 238-42.
9. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56: 918-28.
10. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
11. CLIP. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-5.
12. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 529-34.
13. Levy I, Sherman M. Staging of hepatocellular carcinoma:assessment of the CLIP, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-5.
14. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-69.
15. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-15.
16. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75 (Suppl 1): 1-12.
17. Bruix J, Sherman M. AASLD practice guideline:management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
18. Takayama T, Makuuchi S, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with high rate of surgical cure. Hepatology 1998; 28: 1241-6.
19. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
20. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
21. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan. Hepatology 2000; 32: 1224-9.
22. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
23. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
24. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
25. Todo S, Furukawa H, Tada M. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007; 11 (Suppl 2): S48-54.
26. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.
27. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-16.
28. Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer Classification: results of a prospective analysis. Arch Surg 2008; 143: 1082-90.
29. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1993; 30: 1434-40.
30. Sarasin F, Majno P, Llovet JM, et al. Live donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness perspective. Hepatology 2001; 33: 1073-9.
31. Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-9.
32. Takayama T, Makuuchi M. Ablation of hepatocellular carcinoma. Jpn J Clin Oncol 2001; 31: 297-8.
33. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8.
34. Hasegawa K, Kokudo N, Makuuchi M. Surgery or ablation for hepatocellular carcinoma? Ann Surg 2008; 247: 557-8.